lupus nephritis
Conditions
Interventions
None listed
Sponsors
Otsuka Pharmaceuticals Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: LN patients are indicated as diagnosed with SLE and following under either (1) or (2), and also following under (3). (1) Individuals diagnosed with LN at the time of SLE diagnosis or after diagnosis (2) Individuals with SLE and any of the following criteria, who should be LN individuals. Individuals who have been seen at least once in the nephrology department at the time of SLE diagnosis or after diagnosis Patients with >1 diagnosis (non-diagnostic medical claim) for acute or chronic renal conditions, including glomerulonephritis (including lupus glomerulonephritis), acute or chronic renal failure, nephritis, ore nephrotic syndrome (including lupus nephrotic syndrome), renal failure, ore proteinuria at the time of SLE diagnosis or after diagnosis. Evidence of ESRD at the time of SLE diagnosis or after diagnosis Evidence use of cyclophosphamide, cyclosporine, rituximab, or tacrolimus at or after SLE diagnosis. (3)Individuals aged 18 years or older at LN examination
Exclusion criteria
Exclusion criteria: Individuals with a diagnosis of LN in the previous from 3 months to 6 months after the first time of LN diagnosis during the inclusion period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPCR Proteinuria (semi-quantitative analysis, -to 4+) | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical events Biochemical tests Renal function tests Hematology tests Vital signs Comorbidities Inpatient/outpatient | — |
Countries
Japan
Contacts
Public ContactShinichi Nishiwaki
Otsuka Pharmaceuticals Co., Ltd Medical Affairs Department
Outcome results
None listed